KR20050083098A - Natural anti-biotics containing the culture broth of leuconostoc kimchii - Google Patents
Natural anti-biotics containing the culture broth of leuconostoc kimchii Download PDFInfo
- Publication number
- KR20050083098A KR20050083098A KR1020040011695A KR20040011695A KR20050083098A KR 20050083098 A KR20050083098 A KR 20050083098A KR 1020040011695 A KR1020040011695 A KR 1020040011695A KR 20040011695 A KR20040011695 A KR 20040011695A KR 20050083098 A KR20050083098 A KR 20050083098A
- Authority
- KR
- South Korea
- Prior art keywords
- natural
- kimchi
- antimicrobial
- present
- cosmetics
- Prior art date
Links
- 239000003242 anti bacterial agent Substances 0.000 title claims description 14
- 241000965142 Leuconostoc kimchii Species 0.000 title claims description 10
- 229940088710 antibiotic agent Drugs 0.000 title description 7
- 230000003115 biocidal effect Effects 0.000 title description 4
- 239000002537 cosmetic Substances 0.000 claims abstract description 18
- 235000013305 food Nutrition 0.000 claims abstract description 17
- 239000004599 antimicrobial Substances 0.000 claims abstract description 12
- 239000003814 drug Substances 0.000 claims abstract description 12
- 239000003443 antiviral agent Substances 0.000 claims description 14
- 239000004480 active ingredient Substances 0.000 claims description 5
- 229940079593 drug Drugs 0.000 claims description 4
- 239000012141 concentrate Substances 0.000 claims description 3
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 229940127557 pharmaceutical product Drugs 0.000 claims 1
- 239000001963 growth medium Substances 0.000 abstract description 20
- 235000021109 kimchi Nutrition 0.000 abstract description 19
- 241000894006 Bacteria Species 0.000 abstract description 17
- 230000000844 anti-bacterial effect Effects 0.000 abstract description 14
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 abstract description 6
- 235000014655 lactic acid Nutrition 0.000 abstract description 3
- 239000004310 lactic acid Substances 0.000 abstract description 3
- 230000002421 anti-septic effect Effects 0.000 abstract description 2
- 230000003020 moisturizing effect Effects 0.000 abstract description 2
- 241000124008 Mammalia Species 0.000 abstract 1
- 238000004321 preservation Methods 0.000 abstract 1
- 230000000845 anti-microbial effect Effects 0.000 description 23
- 239000000243 solution Substances 0.000 description 18
- 210000004027 cell Anatomy 0.000 description 15
- 239000000203 mixture Substances 0.000 description 12
- 239000000047 product Substances 0.000 description 11
- 241000700605 Viruses Species 0.000 description 8
- 230000000840 anti-viral effect Effects 0.000 description 8
- 239000003755 preservative agent Substances 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 7
- 239000002609 medium Substances 0.000 description 7
- 230000000813 microbial effect Effects 0.000 description 7
- 244000005700 microbiome Species 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 108010053775 Nisin Proteins 0.000 description 5
- NVNLLIYOARQCIX-MSHCCFNRSA-N Nisin Chemical compound N1C(=O)[C@@H](CC(C)C)NC(=O)C(=C)NC(=O)[C@@H]([C@H](C)CC)NC(=O)[C@@H](NC(=O)C(=C/C)/NC(=O)[C@H](N)[C@H](C)CC)CSC[C@@H]1C(=O)N[C@@H]1C(=O)N2CCC[C@@H]2C(=O)NCC(=O)N[C@@H](C(=O)N[C@H](CCCCN)C(=O)N[C@@H]2C(NCC(=O)N[C@H](C)C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCSC)C(=O)NCC(=O)N[C@H](CS[C@@H]2C)C(=O)N[C@H](CC(N)=O)C(=O)N[C@H](CCSC)C(=O)N[C@H](CCCCN)C(=O)N[C@@H]2C(N[C@H](C)C(=O)N[C@@H]3C(=O)N[C@@H](C(N[C@H](CC=4NC=NC=4)C(=O)N[C@H](CS[C@@H]3C)C(=O)N[C@H](CO)C(=O)N[C@H]([C@H](C)CC)C(=O)N[C@H](CC=3NC=NC=3)C(=O)N[C@H](C(C)C)C(=O)NC(=C)C(=O)N[C@H](CCCCN)C(O)=O)=O)CS[C@@H]2C)=O)=O)CS[C@@H]1C NVNLLIYOARQCIX-MSHCCFNRSA-N 0.000 description 5
- 239000004309 nisin Substances 0.000 description 5
- 235000010297 nisin Nutrition 0.000 description 5
- 238000001228 spectrum Methods 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 102000044503 Antimicrobial Peptides Human genes 0.000 description 4
- 108700042778 Antimicrobial Peptides Proteins 0.000 description 4
- 241000282412 Homo Species 0.000 description 4
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 4
- 108010059993 Vancomycin Proteins 0.000 description 4
- 239000000284 extract Substances 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 241000712461 unidentified influenza virus Species 0.000 description 4
- 229960003165 vancomycin Drugs 0.000 description 4
- MYPYJXKWCTUITO-LYRMYLQWSA-N vancomycin Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-N 0.000 description 4
- MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 description 4
- 241000233866 Fungi Species 0.000 description 3
- 238000000855 fermentation Methods 0.000 description 3
- 230000004151 fermentation Effects 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 238000011081 inoculation Methods 0.000 description 3
- 239000002953 phosphate buffered saline Substances 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 108010062877 Bacteriocins Proteins 0.000 description 2
- 240000006024 Lactobacillus plantarum Species 0.000 description 2
- 235000013965 Lactobacillus plantarum Nutrition 0.000 description 2
- 241000271610 Leuconostoc kimchii IMSNU 11154 Species 0.000 description 2
- RJQXTJLFIWVMTO-TYNCELHUSA-N Methicillin Chemical compound COC1=CC=CC(OC)=C1C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 RJQXTJLFIWVMTO-TYNCELHUSA-N 0.000 description 2
- 241000191967 Staphylococcus aureus Species 0.000 description 2
- 229930013930 alkaloid Natural products 0.000 description 2
- 230000003712 anti-aging effect Effects 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- FUWUEFKEXZQKKA-UHFFFAOYSA-N beta-thujaplicin Chemical compound CC(C)C=1C=CC=C(O)C(=O)C=1 FUWUEFKEXZQKKA-UHFFFAOYSA-N 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 229930003935 flavonoid Natural products 0.000 description 2
- 150000002215 flavonoids Chemical class 0.000 description 2
- 235000017173 flavonoids Nutrition 0.000 description 2
- 239000005452 food preservative Substances 0.000 description 2
- 235000019249 food preservative Nutrition 0.000 description 2
- 239000002054 inoculum Substances 0.000 description 2
- 229940072205 lactobacillus plantarum Drugs 0.000 description 2
- 244000144972 livestock Species 0.000 description 2
- 239000006210 lotion Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 229960003085 meticillin Drugs 0.000 description 2
- 230000002906 microbiologic effect Effects 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- YSTQYYLSLHMSGR-RJMJUYIDSA-N (2R,3R,4S,5R,6S)-2-(hydroxymethyl)-6-[(2R,3S,4R,5R)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxane-3,4,5-triol 2-hydroxypropanoic acid Chemical compound CC(O)C(O)=O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@H]1[C@H](O)[C@@H](O)C(O)O[C@@H]1CO YSTQYYLSLHMSGR-RJMJUYIDSA-N 0.000 description 1
- NSMXQKNUPPXBRG-SECBINFHSA-N (R)-lisofylline Chemical compound O=C1N(CCCC[C@H](O)C)C(=O)N(C)C2=C1N(C)C=N2 NSMXQKNUPPXBRG-SECBINFHSA-N 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N 4-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 241000228245 Aspergillus niger Species 0.000 description 1
- PYIXHKGTJKCVBJ-UHFFFAOYSA-N Astraciceran Natural products C1OC2=CC(O)=CC=C2CC1C1=CC(OCO2)=C2C=C1OC PYIXHKGTJKCVBJ-UHFFFAOYSA-N 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- NDVRQFZUJRMKKP-UHFFFAOYSA-N Betavulgarin Natural products O=C1C=2C(OC)=C3OCOC3=CC=2OC=C1C1=CC=CC=C1O NDVRQFZUJRMKKP-UHFFFAOYSA-N 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 240000007124 Brassica oleracea Species 0.000 description 1
- 235000003899 Brassica oleracea var acephala Nutrition 0.000 description 1
- 235000011301 Brassica oleracea var capitata Nutrition 0.000 description 1
- 235000001169 Brassica oleracea var oleracea Nutrition 0.000 description 1
- 235000002566 Capsicum Nutrition 0.000 description 1
- 240000000560 Citrus x paradisi Species 0.000 description 1
- 244000000626 Daucus carota Species 0.000 description 1
- 235000002767 Daucus carota Nutrition 0.000 description 1
- 206010012442 Dermatitis contact Diseases 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- DWPCPZJAHOETAG-IMJSIDKUSA-N L-lanthionine Chemical compound OC(=O)[C@@H](N)CSC[C@H](N)C(O)=O DWPCPZJAHOETAG-IMJSIDKUSA-N 0.000 description 1
- 241000192132 Leuconostoc Species 0.000 description 1
- 241000192129 Leuconostoc lactis Species 0.000 description 1
- 241000192130 Leuconostoc mesenteroides Species 0.000 description 1
- 241001468196 Leuconostoc pseudomesenteroides Species 0.000 description 1
- 241000218378 Magnolia Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000228143 Penicillium Species 0.000 description 1
- IHPVFYLOGNNZLA-UHFFFAOYSA-N Phytoalexin Natural products COC1=CC=CC=C1C1OC(C=C2C(OCO2)=C2OC)=C2C(=O)C1 IHPVFYLOGNNZLA-UHFFFAOYSA-N 0.000 description 1
- 241000758706 Piperaceae Species 0.000 description 1
- 244000088415 Raphanus sativus Species 0.000 description 1
- 235000006140 Raphanus sativus var sativus Nutrition 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 206010041925 Staphylococcal infections Diseases 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- TUFYVOCKVJOUIR-UHFFFAOYSA-N alpha-Thujaplicin Natural products CC(C)C=1C=CC=CC(=O)C=1O TUFYVOCKVJOUIR-UHFFFAOYSA-N 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 229960001950 benzethonium chloride Drugs 0.000 description 1
- UREZNYTWGJKWBI-UHFFFAOYSA-M benzethonium chloride Chemical compound [Cl-].C1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 UREZNYTWGJKWBI-UHFFFAOYSA-M 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 239000013522 chelant Substances 0.000 description 1
- 229960005091 chloramphenicol Drugs 0.000 description 1
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 1
- 230000007665 chronic toxicity Effects 0.000 description 1
- 231100000160 chronic toxicity Toxicity 0.000 description 1
- 230000002301 combined effect Effects 0.000 description 1
- 238000010835 comparative analysis Methods 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 208000010247 contact dermatitis Diseases 0.000 description 1
- 239000008406 cosmetic ingredient Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- -1 etc. for a long time Substances 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 235000021107 fermented food Nutrition 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- DWPCPZJAHOETAG-UHFFFAOYSA-N meso-lanthionine Natural products OC(=O)C(N)CSCC(N)C(O)=O DWPCPZJAHOETAG-UHFFFAOYSA-N 0.000 description 1
- 208000015688 methicillin-resistant staphylococcus aureus infectious disease Diseases 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- PGSADBUBUOPOJS-UHFFFAOYSA-N neutral red Chemical compound Cl.C1=C(C)C(N)=CC2=NC3=CC(N(C)C)=CC=C3N=C21 PGSADBUBUOPOJS-UHFFFAOYSA-N 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 239000000280 phytoalexin Substances 0.000 description 1
- 150000001857 phytoalexin derivatives Chemical class 0.000 description 1
- 239000001965 potato dextrose agar Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 229930007845 β-thujaplicin Natural products 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L3/00—Preservation of foods or foodstuffs, in general, e.g. pasteurising, sterilising, specially adapted for foods or foodstuffs
- A23L3/34—Preservation of foods or foodstuffs, in general, e.g. pasteurising, sterilising, specially adapted for foods or foodstuffs by treatment with chemicals
- A23L3/3454—Preservation of foods or foodstuffs, in general, e.g. pasteurising, sterilising, specially adapted for foods or foodstuffs by treatment with chemicals in the form of liquids or solids
- A23L3/3463—Organic compounds; Microorganisms; Enzymes
- A23L3/3571—Microorganisms; Enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/99—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from microorganisms other than algae or fungi, e.g. protozoa or bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
- A61Q17/005—Antimicrobial preparations
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/31—Leuconostoc
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Nutrition Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Birds (AREA)
- Dermatology (AREA)
- Cosmetics (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Abstract
본 발명은 한국 김치에서 발견된 새로운 유산균 류코노스톡 김치아이의 배양액의 천연항균효과에 관한 것으로, 좀 더 상세하게는 식품, 의약품, 화장품, 생활용품 등에서 방부 및 보습기능을 가짐으로써 상기 제품의 보존 안정성을 높여 줄 수 있고 사람을 포함한 포유류에서 안전하고 내성이 유발되지 않는 천연항균제로서의 류코노스톡 김치아이 배양액의 새로운 용도에 관한 것이다. The present invention relates to the natural antibacterial effect of the culture of the new lactic acid bacteria Leukonostok Kimchi I found in Korea Kimchi, more specifically, the preservation of the product by having an antiseptic and moisturizing function in food, medicine, cosmetics, household goods, etc. The present invention relates to a novel use of leukonostock kimchi eye culture medium as a natural antimicrobial agent that can increase stability and is safe and does not cause resistance in mammals including humans.
Description
본 발명은 항산화 및 피부보습 기능과 항노화 활성을 가지면서 항균력이 우수한 천연 항균제에 관한 것으로서, 보다 구체적으로는, 류코노스톡 김치아이(Leuconostoc kimchii)의 배양액, 배양액의 농축액 또는 배양액의 건조물을 주 활성성분으로 하며, 항산화 기능과 항노화 활성을 가지며, 항균력이 높고, 항균 스펙트럼이 광범위한 다기능성 천연항균제에 관한 것이다.The present invention while having the antioxidant and skin moisturizing and anti-aging activity as antibacterial activity is related to the excellent natural antimicrobial agent, more specifically, current Pocono stock kimchi child main culture medium, concentrated liquid or culture solution of the dried product of the culture of (Leuconostoc kimchii) The present invention relates to a multifunctional natural antimicrobial agent having an active ingredient, having an antioxidant function and an anti-aging activity, having high antibacterial activity, and having a broad antibacterial spectrum.
식품, 의약품, 화장품 등의 품질을 오랫동안 유지하기 위해서는 미생물에 의한 부패를 막아주는 방부제가 필수적인데, 제품 특성상 유통기간이 비교적 길며 미생물 영양원이 많은 화장품의 경우는 더욱 그러하다.In order to maintain the quality of food, medicine, cosmetics, etc. for a long time, preservatives that prevent decay by microorganisms are essential, but in the case of cosmetics with a long shelf life and a lot of microbial nutrients due to the characteristics of the product.
그러나, 기존의 방부제로서 가장 안전하며 화장품, 의약품에 범용적으로 사용되는 파라벤류의 방부제들 조차 피부알러지(Andrea Counti 등, Contact Dermatitis, 1997,37;35-36)와 환경호르몬으로서의 가능성(Edwin 등, Tocxicology and Applied Pharmacology,1998,153;12-19) 및 내성균 유발이라는 문제점을 가지고 있다. 뿐만 아니라 식품용 방부제들은 허용된 기준내의 사용도 불신되고 있고 지속적인 체내 축적으로 인한 급ㆍ만성 독성, 돌연변이 유발 등의 새로운 문제 가능성이 대두되고 있다(신동화, 식품과학과 산업,1990,23(4) 68-72).However, even parabens preservatives, which are the safest as preservatives and are widely used in cosmetics and medicines, are allergic to skin (Andrea Counti et al., Contact Dermatitis, 1997,37; 35-36) and their potential as environmental hormones (Edwin et al. , Tocxicology and Applied Pharmacology, 1998,153; 12-19) and resistant bacteria. In addition, preservatives for foods are distrusted in the use of acceptable standards, and new problems such as acute and chronic toxicity and mutagenesis due to continuous accumulation in the body are emerging (Xinhua, Food Science and Industry, 1990, 23 (4) 68). -72).
이러한 문제점들로 인하여 제품의 안전성과 경제성이 우수한 천연방부제에 대한 연구가 지속되고 있으며 그 결과로 향신류, 정유, 한약재 등 동ㆍ식물기원의 추출물과 박테리오신 같은 미생물 기원의 천연항균성물질이 보고되고 있다. Due to these problems, research on natural preservatives with excellent safety and economical efficiency of products is ongoing, and as a result, extracts of animal and plant origin such as spices, essential oils, herbal medicines, and natural antimicrobial substances such as bacteriocin have been reported. .
천연의 항균성 물질로 알칼로이드(alkaloid), 후라보노이드(flavonoid), 피토알렉신(Phytoalexin), 항균펩타이드 등이 알려져 있으며, 유기산과 지방산 등의 항균성에 대한 것도 알려져 있다. 이들 대부분은 산의 pH에 의한 효과와 킬레이트에 의한 효과가 주 메커니즘일 것으로 추정된다.(El-shenawa, MA 등, J.Food Protec. 1989,52(11):771-778 ) (Bizri,JN 등,J food Science,1994,59(1),130-135) Alkaloids (alkaloids), flavonoids (phytonoids), phytoalexin (antibacterial peptides), antimicrobial peptides and the like are known as natural antimicrobial substances, and antimicrobial agents such as organic acids and fatty acids are also known. Most of them are estimated to be the main mechanism of acid pH and chelate effects (El-shenawa, MA et al., J. Food Protec. 1989,52 (11): 771-778) (Bizri, JN). J Food Science, 1994, 59 (1), 130-135).
그러나 보고된 천연항균성 물질의 대부분은 색취, 안정성 저하, 좁은 항균 스펙트럼, 제형상의 문제점 등으로 인하여 상용화되지 못하고 있으며, 편백 추출물인 희노키티올(Hinokitiol), 목련추출물인 메그노놀(Megnonol), 자몽종자 추출물인 DF-100 등 극히 일부만이 상용화되고 있다.However, most of the reported natural antimicrobial substances have not been commercialized due to color, deterioration of stability, narrow antimicrobial spectrum, and problems in formulation.They are a white extract, hinokitiol, magnolia extract, megnonol and grapefruit. Only a few, such as seed extract DF-100, are commercially available.
이 중에서 가장 제품개발이 앞선 DF-100의 경우에 항균력은 DF-100에 포함된 유기산 및 합성보존료인 Benzethonium chloride 때문인 것으로 알려져 있으며, 그 외 다른 천연항균제 등은 경제성이 낮거나 좁은 항균 스펙트럼 또는 물성에 의한 사용범위의 제한성 등의 문제를 가지고 있어 진보되고 제품화 개발이 가능한 천연항균제가 절실한 실정이다.In the case of DF-100, which is the most developed product among them, the antibacterial activity is known to be due to the organic acid and synthetic preservative Benzethonium chloride contained in DF-100. Due to the limitation of the scope of use, such as natural antibacterial agent that is capable of advanced and commercialized development is urgent.
한편, 현재 일반제품에 사용되고 있는 항균제는 제품의 품질을 유지하는 차원이 아니라 미생물에 의한 사람 및 가축의 질병을 예방하고 치료하기 위하여 합성항생제가 범용되고 있으나, 오용 및 남용으로 인해 다양한 내성균주가 나타나 병원에서는 감염증을 치료하기 위해 고단위의 항생제를 사용하여야 하는 악순환의 고리를 형성하고 있고, 가축에게도 원인균의 감수성이 떨어지고 항생제 잔류하는 공중보건상 중요한 문제가 대두되고 있다. Meanwhile, antimicrobial agents currently used in general products are not intended to maintain product quality, but synthetic antibiotics are widely used to prevent and treat diseases of humans and livestock caused by microorganisms, but various resistant strains have appeared due to misuse and abuse. Esau forms a vicious loop that requires the use of high-level antibiotics to treat infections, and the public health issues that cause susceptibility of causative organisms to the livestock and that antibiotics remain.
메티실린 저항성 포도상구균(Methicillin Resistant Staphylococcus aureus;MRSA) (Voss,A등, Int J. Antimicrob.Agents, 1995,5:101-106)에 대처하기 위해 2가지 이상의 항생제를 복합적으로 사용하거나 반코마이신(Vancomycin)을 사용하고 있다. 그러나 반코마이신에 대하여 저항성을 갖는 장내 세균(vancomycin-resistant enterococci)(Billot-klein D. Antimicrob. Agents, Chemother,1992,36:1487-1490)과 같은 내성균주가 출현하고 있다.Methicillin-resistant Staphylococcus aureus (Methicillin Resistant Staphylococcus aureus; MRSA) : use of two or more antibiotics to combat (Voss, such as A, Int J. Antimicrob.Agents, 1995,5 101-106) or a combination of vancomycin (Vancomycin ) Is used. However, resistant strains such as vancomycin-resistant enterococci (Billot-klein D. Antimicrob. Agents, Chemother, 1992, 36: 1487-1490) resistant to vancomycin have emerged.
그에 따라 근래에는 항생제의 감수성을 높이기 위해 천연물에서 후라보노이드와 같이 사용하여 감수성을 높였다는 보고가 있으며(IAIN X,Liu 등 J. Pharm. Pharmacol, 2000,52:361-366), 항균펩타이드(Giacometti A 등, J. Antimicrob. Chemother 2000 Nov;46(5):807-811)도 병용효과를 위한 대안으로 많은 연구가 진행되었지만, 항균펩타이드는 항균성만 나타내는 제한성이 있으며 경제적 대량생성방법에 문제가 있다(Lee JH 등 , Protein. Expr. Purif. 1998 Feb;12(1),53-60). Accordingly, in recent years, it has been reported that natural products were used with flavonoids to increase the sensitivity of antibiotics (IAIN X, Liu et al. J. Pharm. Pharmacol, 2000, 52: 361-366), and antimicrobial peptides (Giacometti A Et al., J. Antimicrob. Chemother 2000 Nov; 46 (5): 807-811), although many studies have been conducted as alternatives for the combined effect, antimicrobial peptides have only limited antimicrobial properties and problems in economic mass production methods. Lee JH et al., Protein.Expr.Purif. 1998 Feb; 12 (1), 53-60).
나이신(nisin)은 식품이나 화장품을 부패시키는 일부 세균에 대한 항균작용을 지니고 있는 펩타이드로 식용세균인 스트렙토코커스 락티스(Streptococcus lactics)의 발효산물로 식품방부제로서의 안전성과 효능이 탁월하여 미국을 포함한 세계 각국에서 우유 및 치즈에 널리 사용되고 있다. 나이신은 란티오닌이라는 아미노산을 함유하여 란티바이오틱스(Lantibiotics)라는 항균물질의 범주에 속하며, FDA에서 식품방부제로의 사용을 허가하였고 CTFA에서도 화장품원료로서 사용을 허가하였다.Nisin is a peptide that has antimicrobial activity against some bacteria that rot food or cosmetics. It is a fermentation product of Streptococcus lactics , an edible bacterium, and has excellent safety and efficacy as a food preservative. It is widely used in milk and cheese around the world. Nisin is included in the category of antimicrobial material, Lantibiotics, containing an amino acid called lanthionine, and has been approved by the FDA as a food preservative and as a cosmetic ingredient by CTFA.
그러나 나이신도 항균력의 범위가 좁은 문제점을 가지고 있다. 나이신은, 예를 들면, 내생포자를 갖는 그람양성균인 바실러스(Bacillus)류나 진핵미생물인 이스트(Yeast)류, 곰팡이(Fungi) 등에는 항균력을 나타내지 못한다.However, nisin also has a narrow range of antibacterial activity. Nisin does not show antibacterial activity, for example, to Bacillus, a gram-positive bacterium having endogenous spores, to Yeast, a fungi, and the like, of eukaryotic microorganisms.
본 발명은 기존의 화학방부제의 인체 유해성을 해결할 수 있는 것으로서, 천연 유래로 안전(인체 무해)하고, 습득이 용이하여 경제적이며, 또한 기존의 천연방부제가 갖는 좁은 범위의 항균 스펙트럼, 더 자세하게는 그람 음성균에만 항균작용을 하는 나이신 같은 항균 펩타이드와는 달리, 거의 모든 미생물군―더 자세하게는 바이러스, 그람음성,양성균, 이스트류, 곰팡이류 등을 포함하는―에 대하여 항균효과가 있을 정도로 항균 스팩트럼이 넓을 뿐만 아니라 물성이 안정하여 다양한 영역에 적용할 수 있는 새로운 천연 항균성 물질을 제공하는 것을 목적으로 한다. The present invention solves the human hazards of conventional chemical preservatives, which are safe from humans (harmless to humans), easy to learn, economical, and also have a narrow range of antimicrobial spectrum of conventional natural preservatives, more specifically Gram. Unlike antimicrobial peptides such as nisin, which only act as antibacterial agents, the antimicrobial spectrum is broad enough to have an antimicrobial effect against almost all microorganisms, more specifically viruses, Gram-negatives, benign bacteria, yeasts, and fungi. In addition, the object of the present invention is to provide a new natural antimicrobial material that is stable in physical properties and can be applied to various areas.
또한 본 발명은 상기 천연 항균성 물질을 함유하는 식품, 의약품 및 화장품을 제공하는 것을 목적으로 한다. It is another object of the present invention to provide a food, medicine and cosmetics containing the natural antimicrobial substance.
전술한 목적을 달성하기 위한 본 발명은, 류코노스톡 김치아이(Leuconostoc kimchii)의 배양액, 배양액의 농축액 또는 배양액의 건조물을 활성성분으로 포함하는 천연항균제 및 천연항바이러스제에 관한 것이다.The present invention for achieving the above object relates to a natural antimicrobial agent and a natural antiviral agent comprising a culture solution of Leuconostoc kimchii , concentrated solution of the culture solution or dried product of the culture as an active ingredient.
한국의 전통 발효음식인 김치(Kimchi)는 배추, 무우, 당근, 고추 등을 유산균 발효 시킨 것으로 한국 성인은 매일 평균 50-200g을 섭취하고 있다. 분류학적으로 다양한 그룹, 예를 들면 류코노스톡 메젠테로이드(Leuconostoc mesenteroides), 류코노스톡 슈도메젠테로이드(Leuconostoc pseudomesenteroides) 그리고 류코노스톡 락티스(Leuconostoc lactis) 뿐만 아니라 락토바실러스 브레비스(Leuconostoc brevis) 와 락토바실러스 플렌타룸(Lactobacillus plantarum)을 포함하는 락토바실러스 군 등의 유산균이 김치의 발효과정에서 발견된다. 그런데 최근에 김정호 교수 등이 한국의 김치에서 새로운 유산균을 발견하여 이를 학계에 보고하였고(Int'l J. of Systematic & Evolutionary Microbiology (2000),50,1915-1919), 서울대 미생물 연구소에서 이 균에 대한 지놈지도를 발표한 바 있다.Kimchi, a traditional Korean fermented food, is a fermented fermentation of cabbage, radish, carrots, peppers, etc. Korean adults consume an average of 50-200g every day. Taxonomically diverse groups such as Leuconostoc mesenteroides , Leuconostoc pseudomesenteroides and Leuconostoc lactis , as well as Leuconostoc brevis and lactose Lactic acid bacteria such as Lactobacillus plantarum , including Lactobacillus plantarum , are found in the fermentation process of kimchi. Recently, Professor Kim Jung-ho discovered a new lactic acid bacterium in Kimchi and reported it to academia (Int'l J. of Systematic & Evolutionary Microbiology (2000), 50,1915-1919). I have published a genome map for Korea.
본 발명은 상기 미생물의 배양액이 강한 항균효과를 보인다는 사실을 발견하여 완성하게 된 것이다. Leuconostoc kimchii IMSNU11154는 서울대학교 미생물연구소의 미생물자원센터에서 분양받았다.The present invention has been completed by finding the fact that the culture medium of the microorganism shows a strong antibacterial effect. Leuconostoc kimchii IMSNU11154 was distributed by the Microbial Resources Center of the Seoul National University Microbiological Research Institute.
본 발명은 또한 상기 류코노스톡 김치아이의 배양액, 배양액의 농축액 또는 배양액의 건조물을 활성성분으로 하는 천연항균제 또는 천연항바이러스제를 함유하는 식품, 의약품 및 화장품에 관한 것이다. The present invention also relates to foods, pharmaceuticals and cosmetics containing a natural antimicrobial agent or a natural antiviral agent as an active ingredient of the culture medium, the concentrated solution of the culture medium or the dried product of the culture medium.
하기 실시예 및 적용예에서 확인된 바와 같이, 본 발명에 의한 천연항균제는 종래 널리 알려져 있고 널리 사용되고 있는 파라벤 보다 월등히 우수하고 넓은 항균 스펙트럼을 가진다. As confirmed in the following examples and applications, the natural antimicrobial agent according to the present invention has an excellent antimicrobial spectrum which is far superior to that of parabens, which are widely known and widely used.
하기 실시예 및 적용예에서 본 발명에 의한 천연항균제 또는 천연항바이러스제를 구체적으로 식품 또는 의약품에 적용하는 실험이 이루어지지는 않았다. 그러나 상기 류코노스톡 김치아이 균주가 김치에서 발견되었고, 김치는 오랜 기간동안 인간에 섭취되면서 그 안전성이 입증된 것이므로 상기 균주는 인체에 무해하며(안전성), 본 발명에 의해 상기 균주의 배양액에 천연항균력 또는 천연항바이러스력이 있다는 것이 확인되었다. 그리고 이 배양액을 여러 제형의 화장품에 적용한 경우 제품이 방부력을 유지하는 것을 확인하였다. 비록 실질적인 실험이 이루어지지 않았다 하더라도, 증명된 화장품과 유사한 제형을 갖는 식품, 음료, 의약품의 경우도 본 발명에 의한 천연항균제 또는 천연항바이러스제를 투입하여 항균력 또는 항바이러스력을 부여할 수 있음은 당업자에게 당연할 것이다.In the following Examples and Applications, the experiment was not specifically applied to the natural antibacterial or natural antiviral agent according to the present invention to food or pharmaceuticals. However, the strain of leukonostock kimchi eye was found in kimchi, and the kimchi was proved to be safe as it was ingested in humans for a long time. Therefore, the strain is harmless to the human body (safety), and thus, the strain is naturally in the culture medium of the strain. It has been confirmed that there is antibacterial or natural antiviral activity. And when the culture was applied to cosmetics of various formulations it was confirmed that the product maintains antiseptic power. Although practical experiments have not been carried out, it is possible for foods, beverages, and medicines having a formulation similar to the certified cosmetics to impart antimicrobial or antiviral power by injecting a natural antimicrobial agent or a natural antiviral agent according to the present invention. Will be taken for granted.
본 발명에 의한 천연항균제 또는 천연항바이러스제를 식품, 의약품 또는 화장품 등에 적용하는 경우, 적용 대상의 특성, 적용 대상의 제조, 유통, 보관 및 사용 양태 등에 따라 0.1~30 부피% 함유되도록 할 수 있다. When the natural antimicrobial agent or the natural antiviral agent according to the present invention is applied to food, medicine or cosmetics, it may be contained in an amount of 0.1 to 30% by volume depending on the characteristics of the application target, the manufacture, distribution, storage and use of the application target.
이하 실시예 및 적용예를 들어 본 발명을 상세히 설명한다. 하기 실시예 등은 본 발명을 설명하고자하는 예시적인 것일 뿐, 이에 의해 본 발명의 기술적 사상의 범위가 변경되거나 축소되는 것은 아니다. 또한 하기 실시예 또는 적용예 이외에 다양한 실시예 또는 적용예가 가능함은 당업자에게 있어 당연할 것이다. Hereinafter, the present invention will be described in detail with reference to Examples and Application Examples. The following examples and the like are merely illustrative of the present invention, and thus the scope of the technical spirit of the present invention is not changed or reduced. It will also be apparent to those skilled in the art that various embodiments or applications are possible in addition to the following examples or applications.
실시예 : 류코노스톡 김치아이의 배양액의 제조EXAMPLES Preparation of Culture Media of Leukonostock Kimchi
분석을 위하여 Leuconostoc kimchii IMSNU11154 균주를 서울대학교 미생물연구소의 미생물자원센터에서 분양받았다.For analysis, the strain Leuconostoc kimchii IMSNU11154 was distributed at the Microbial Resource Center of the Seoul National University Microbiological Research Institute.
100 ml의 MRS(Difco) broth를 121℃에서 15분간 고압멸균 후, Leuconostoc kimchii를 접종하고 30℃에서 16시간동안 진탕 배양하였다. 배양액을 5000 X g로 3분간 원심 분리한 다음, bacteria-free 상태로 유지하기 위하여 pore size 0.22 μm인 여과막 (membrane filter) 을 이용하여 여과하였다.100 ml of MRS (Difco) broth was autoclaved at 121 ° C. for 15 minutes, inoculated with Leuconostoc kimchii and incubated at 30 ° C. for 16 hours. The culture solution was centrifuged at 5000 X g for 3 minutes, and then filtered using a membrane filter having a pore size of 0.22 μm to maintain bacteria-free state.
배양액 농축의 경우는 위에서 얻은 배양액을 10,000 Da membrane을 통과시켜 여과액을 취한 후, 1,000 Da membrane 으로 농축하였다. 농축한 배양액을 bacteria-free 상태로 유지하기 위하여 pore size 0.22 μm 인 여과막 (membrane filter) 을 이용해 여과하였다.In case of concentration of the culture solution, the culture solution obtained above was filtered through 10,000 Da membrane, and then concentrated to 1,000 Da membrane. The concentrated culture solution was filtered using a membrane filter (pore size 0.22 μm) to maintain bacteria-free state.
여과액의 최종 pH는 항상 7이 되도록 조정하여 사용하였다. The final pH of the filtrate was adjusted to 7 at all times.
적용예 1 : 류코노스톡 김치아이의 배양액의 항균력 확인 1Application Example 1: Check the antimicrobial activity of the culture medium of the leukonostock kimchi eye 1
전술한 실시예에 의해 얻어진 본 발명에 의한 류코노스톡 김치아이(Leuconostoc kimchii)균의 배양액의 항균력을 측정하였다.The antimicrobial activity of the culture solution of Leuconostoc kimchii bacteria according to the present invention obtained by the above-described example was measured.
(1) 오염균의 준비(1) Preparation of contaminating bacteria
본 발명에 의한 류코노스톡 김치아이(Leuconostoc kimchii)균의 배양액의 항균력 측정을 위하여 하기 표 1과 같이 다양한 분류학적 분포를 가지는 대상 미생물을 선정하였다.In order to measure the antimicrobial activity of the culture medium of Leuconostoc kimchii bacteria according to the present invention, the target microorganisms having various taxonomic distributions were selected as shown in Table 1 below.
Bacteria 및 yeast는 항균력 측정실험 실시 1일전 상기 표 1에 기재되어 있는 배지 50ml(250ml 플라스크)에 접종하여 overnight 배양하였다. Mold는 potato dextrose agar plate나 slant에서 1~2주 정도 사전 배양하였다. 이때 진균류 배지에는 항생제 chloramphenicol 을 넣어 주어 세균이 자라지 못하도록 하였다.Bacteria and yeast were inoculated in 50 ml (250 ml flask) of the medium described in Table 1 one day before the antimicrobial activity measurement experiment was incubated overnight. Mold was pre-incubated for 1-2 weeks in potato dextrose agar plate or slant. At this time, antibiotics chloramphenicol were added to the fungal medium to prevent bacteria from growing.
먼저, 그룹 1에 속하는 E.coli, S.aureus, P.aeruginosa를 overnight 배양한 후 1 : 1 : 1 로 혼합하여 그룹 1 접종액을 준비하였다. 그룹 4에 속하는 몰드는, 1~2 주 배양한 배지에 식염수 10ml을 넣고 표면을 살살 긁어서 포자를 harvest 한 다음 1/10 ~ 1/100 희석(A.niger는 1/10~1/100, Penicillium은 최소 1/100 정도로 희석하여야 counting 할 수 있는 정도가 됨)하여 Hemocytometer로 직접 counting 해서 cell #를 측정하여 접종액을 준비였다. 최종적으로 접종액의 미생물 숫자는 Bacteria는 경우는 108 cells/ml, yeast와 mold는 107 cells/ml이 되도록 멸균된 생리식염수를 이용하여 희석하였다.First, E. coli , S. aureus , and P. aerruginosa belonging to group 1 overnight incubation, and then mixed 1: 1: 1 to prepare a group 1 inoculum. In the mold belonging to group 4, 10 ml of saline solution was added to the culture medium for 1-2 weeks, and the surface was gently scraped to harvest spores, and then diluted 1/10 to 1/100 ( A.niger is 1/10 to 1/100, Penicillium The dilution is at least 1/100 to be able to count), and the inoculation solution was prepared by counting directly with a hemocytometer and measuring cell #. Finally, the inoculum was diluted to 10 8 cells / ml for Bacteria and 10 7 cells / ml for yeast and mold.
(2) 오염균의 접종 및 항균력 분석(2) Inoculation of contaminating bacteria and analysis of antibacterial activity
실시예 1에서 얻은 본 발명에 의한 류코노스톡 김치아이(Leuconostoc kimchii)균의 배양액 50ml이 든 14개의 conical tube를 준비하고, 각각의 튜브에 그룹 1 접종액 0.5ml(최종 균 농도는 약 107 cells/ml), 그룹 2 미생물 overnight 배양액을 0.4~0.45ml, 그룹 3 overnight 배양액 0.5ml(최종 균 농도는 약 105 cells/ml) 및 그룹 4에 속하는 몰드 배양액(각 몰드의 최종 균 농도가 각의 최종 농도가 5×105 cells/ml정도가 되도록)을 접종한다(각각 4중 실험).Fourteen conical tubes containing 50 ml of the culture medium of Leuconostoc kimchii according to the present invention obtained in Example 1 were prepared, and 0.5 ml of Group 1 inoculation solution (final bacteria concentration was about 10 7 in each tube). cells / ml), 0.4 to 0.45 ml of group 2 microorganism overnight culture medium, 0.5 ml of group 3 overnight culture medium (final cell concentration is about 10 5 cells / ml) and mold cultures of group 4 (final cell concentration of each mold is Inoculate to a final concentration of 5 × 10 5 cells / ml (four experiments each).
그룹 1 및 그룹 2가 접종된 샘플은 30~35℃에서, 그룹 3 및 그룹 4가 접종된 샘플은 25~30℃에서 배양하면서 접종 후 0일, 1일, 2일, 7일, 14일, 21일, 28일이 경과한 시점에서 샘플 일부(0.1ml 또는 0.1g)을 취하여 준비된 plate에 spreading 하고 incubator에서 배양하였다. 배양 2일 후 (그룹1의 경우)와 배양 1주일 후(그룹2~그룹.4의 경우) plate를 꺼내어 생존균수를 측정하여 하기 표 2에 나타내었다. 표 2에 기재된 수치는 4개 실험 샘플의 평균값이다. Samples inoculated with group 1 and group 2 were incubated at 30-35 ° C., samples inoculated with group 3 and group 4 were incubated at 25-30 ° C. with 0, 1, 2, 7, 14, At 21 and 28 days, a portion of the sample (0.1ml or 0.1g) was taken and spread on the prepared plate and incubated in an incubator. After 2 days of culture (for group 1) and 1 week after culture (for groups 2 to 4), the plates were taken out, and the number of viable bacteria was measured and shown in Table 2 below. The numerical values shown in Table 2 are average values of four experimental samples.
적용예 2 : 류코노스톡 김치아이의 배양액의 항균력 확인 2Application Example 2: Confirmation of antimicrobial activity of the culture medium of the leukonostock kimchi eye
본 발명에 의한 류코노스톡 김치아이의 배양액의 항균력이 화장품에서도 작용하는 지를 확인하기 위하여, 널리 알려진 기초화장품의 하나인 스킨로션에 본 발명에 의한 배양액을 적용하여 항균력을 기존의 가장 흔히 사용되는 파라벤과 비교 분석하였다(하기 표 3의 시험조성물 1, 2,3). 그러나 본 발명의 적용 화장품 조성물예로서 스킨로션에 제한되는 것은 아니다. In order to confirm whether the antimicrobial activity of the culture solution of the leukonostock kimchi eye according to the present invention also works in cosmetics, by applying the culture solution according to the present invention to a skin lotion which is one of the well-known basic cosmetics, the antibacterial activity of the paraben is most commonly used. And the comparative analysis (Test Composition 1, 2, 3 in Table 3). However, the present invention is not limited to skin lotion as an example of the applied cosmetic composition.
실험방법은 실시예 1에서 김치 유산균 배양액에 행하였던 실험방법과 동일하게 시험조성물 예 1, 2, 3을 각각 샘플로 하여 그룹 1 ~그룹 4의 미생물군을 실시예 1과 동일하게 강제 접종하여 동일한 온도에서 배양하여 최종적으로 확인된 14일 경과 후 항균력의 상태를 확인하였다(도 1 내지 도 4 참조). 도 1, 2, 3, 4는 각각 그룹 1, 그룹 2, 그룹 3, 그룹 4를 대상으로 한 실험결과 사진이며, 도에서 1, 2, 3은 각각 상기 표 3에서의 시험조성물 1, 2, 3을 나타낸다.Experimental method was inoculated in the same manner as in Example 1 by inoculating the microbial group of Groups 1 to 4 in the same manner as in Example 1, using the test compositions Examples 1, 2, and 3 as samples, respectively, in the same manner as in the Kimchi lactic acid bacteria culture medium in Example 1. After culturing at a temperature of 14 days finally confirmed the state of the antimicrobial activity (see Figures 1 to 4). 1, 2, 3, and 4 are photographs of the experiment results of Group 1, Group 2, Group 3, and Group 4, respectively. In Figures 1, 2, and 3 are the test compositions 1, 2, 3 is shown.
도에서 볼 수 있듯이, 전체적으로, 모든 실험대상 그룹의 시험조성물 1에서 많은 균의 생장이 확인되었다.(도 4를 제외하고는, 시험조성물 1에서 너무 많은 미생물 콜로니들이 발생함에 따라 배지위에 전체적으로 미생물층이 형성되었음. 이에 따라 사진상으로는 마치 미생물 콜로니가 없는 것처럼 보임.) 다만 그룹 4(곰팡이류)의 경우 오히려 파라벤이 함유된 시험조성물 2에서 가장 곰팡이의 생장이 많았다. 반면에 모든 그룹의 시험조성물 3 즉, 본 발명에 의한 천연항생제를 함유한 조성물에서는 균의 생장이 거의 발견되지 않았다.As can be seen in the figure, as a whole, the growth of a large number of bacteria in the test composition 1 of all subject groups was confirmed (except in FIG. 4, too many microbial colonies in the test composition 1 as a whole microbial layer on the medium. As a result, it appears as if there are no microbial colonies in the photograph.) However, in group 4 (fungus), the most mold growth was found in the test composition 2 containing parabens. On the other hand, almost no growth was found in the test composition 3 of all groups, that is, the composition containing the natural antibiotic according to the present invention.
이에 따라 본 발명에 의한 천연항생제가 우수하면서도 폭넓은 스펙트럼을 가지는 항생효과를 가지고 있음이 확인되었다. Accordingly, it was confirmed that the natural antibiotic according to the present invention has an excellent antibiotic effect while having a broad spectrum.
적용예 3 : 류코노스톡 김치아이의 항바이러스력 확인Application Example 3: Identification of antiviral activity of leukonostock kimchi eye
본 발명에 의한 류코노스톡 김치아이의 배양액이 항바이러스력을 가지고 있는 지를 확인하기 위하여, 인플루엔자 바이러스를 본 발명에 의한 배양액으로 처리하는 실험을 수행하였다.In order to confirm whether the culture medium of the leukonostock kimchi eye according to the present invention has antiviral activity, an experiment was performed in which the influenza virus was treated with the culture medium according to the present invention.
Madin-Darby Canine Kidney cell(MDCK) ATCC CCL 34와 Influenza virus A1H3N2를 국립보건원으로부터 분양받았다. MDCK cell(80% confluent in 6 well plates)은 pH 7.4인 Phosphate-Buffered Saline(PBS, GIBCO사 제품)으로 세 번 세척하였다. Influenza virus는 Fetal Bovine Serum이 들어 있지 않은 Dulbecco's Modified Eagle Medium(MEM medium, GIBCO사 제품)으로 serial dilution 하였다.Madin-Darby Canine Kidney cell (MDCK) ATCC CCL 34 and Influenza virus A1H3N2 were distributed from the National Institutes of Health. MDCK cells (80% confluent in 6 well plates) were washed three times with Phosphate-Buffered Saline (PBS, manufactured by GIBCO) at pH 7.4. Influenza virus was serially diluted with Dulbecco's Modified Eagle Medium (MEM medium, manufactured by GIBCO) without Fetal Bovine Serum.
Influenza virus를 MDCK cell에 0.1-0.2 ml/ 6 well plate의 농도로 접종한 후, 상기 희석액(대조군) 또는 Leuconostoc kimchii의 배양액(처리군)을 10%가 되도록 각 well에 첨가하고 33-34℃에서 1 시간동안 배양하였다. 이때 매 15분 마다 plate를 흔들어 주었다. virus를 제거하고 세포를 PBS로 세척한 후, 2배 농축된 MEM과 2배 농축된 agarose(2%),그리고 trypsin (1.2 g/ml)을 포함하고 있는 배지로 세포를 덮어 주고 42℃를 유지시켜 주었다. 배지를 실온에서 고형화시킨 다음, 33-34℃에서 3-4 일 동안 clear zone이 관측될 때까지 배양하였다. clear zone이 나타나면 5 % glutaraldehyde 100-200 μl를 각 well에 첨가하여 33-34℃에서 2 시간동안 방치하여 고정시켰다. Plate들을 물로 세척하여 덮은 배지를 제거한 후, 0.1% neutral red로 염색하였다. 이때, 죽은 세포는 백색으로 살아 있는 세포는 적색으로 염색되었다(도 5). 도의 대조군 및 처리군에서 왼쪽 플레이트는 바이러스를 처리하지 않은 샘플이다.After influenza virus was inoculated into MDCK cells at a concentration of 0.1-0.2 ml / 6 well plates, the dilution (control) or the culture solution of Leuconostoc kimchii (treatment group) were added to each well to 10% and at 33-34 ° C. Incubated for 1 hour. At this time, the plate was shaken every 15 minutes. After removing the virus and washing the cells with PBS, the cells were covered with medium containing 2 times concentrated MEM, 2 times concentrated agarose (2%), and trypsin (1.2 g / ml) and maintained at 42 ° C. I let you. The medium was solidified at room temperature and then incubated at 33-34 ° C. for 3-4 days until clear zone was observed. When clear zones appeared, 100-200 μl of 5% glutaraldehyde was added to each well and left at 33-34 ° C. for 2 hours to fix. Plates were washed with water to remove the covered medium and stained with 0.1% neutral red. At this time, dead cells were white and living cells were stained red (FIG. 5). The left plate in the control and treatment groups in FIG. Is a sample without virus treatment.
도에서 볼 수 있듯이, 바이러스가 처리된 대조군(대조군 사진의 오른쪽 플레이트)에서는 바이러스가 숙주세포를 활발히 공격한 결과 흰색의 바이러스 플라크가 많이 발생하였다. 반면, 본 발명에 의한 항바이러스제가 함유된 상태에서 바이러스가 처리된 처리군(처리군 사진의 오른쪽 플레이트)에서는 대조군에서와는 월등하게 적은 수의 바이러스 플러크가 형성되었다.As can be seen in the virus-treated control group (right plate of the control picture), the virus actively attacked the host cell, resulting in a lot of white virus plaques. On the other hand, in the treatment group in which the virus was treated in the state containing the antiviral agent according to the present invention (right plate of the treatment group photo), a significantly smaller number of virus flushes were formed than in the control group.
따라서, 본 발명에 의한 항바이러스제의 항바이러스력이 확인되었다. Therefore, the antiviral power of the antiviral agent by this invention was confirmed.
이상 검토하고 증명한 바와 같이, 본 발명에 의한 류코노스톡 김치아이의 배양액, 배양액의 농축액 또는 배양액의 건조물은 넓고 우수한 항균력 및 항바이러스력을 보인다. 따라서 이를 활용하는 경우, 안전하고 효과적으로 식품, 의약품, 화장품 등에 항균력 또는 항바이러스력을 부여할 수 있게 된다.As discussed and proved above, the culture solution of the leukonostock kimchi eye, the concentrate of the culture solution, or the dried product of the culture medium of the present invention exhibit a wide and excellent antibacterial and antiviral activity. Therefore, when utilizing this, it is possible to give antimicrobial or antiviral power to food, medicine, cosmetics safely and effectively.
도 1 내지 도 4는 본 발명에 의한 류코노스톡 김치아이 배양액의 항균력을 보여주는 실험결과 사진.1 to 4 is a photograph of the experimental results showing the antimicrobial activity of leukonostock kimchi eye culture solution according to the present invention.
도 5는 본 발명에 의한 류코노스톡 김치아이 배양액의 항바이러스력을 보여주는 실험결과 사진. Figure 5 is a photograph of the experimental results showing the antiviral power of the leukonostock kimchi eye culture medium according to the present invention.
Claims (14)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020040011695A KR20050083098A (en) | 2004-02-21 | 2004-02-21 | Natural anti-biotics containing the culture broth of leuconostoc kimchii |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020040011695A KR20050083098A (en) | 2004-02-21 | 2004-02-21 | Natural anti-biotics containing the culture broth of leuconostoc kimchii |
Publications (1)
Publication Number | Publication Date |
---|---|
KR20050083098A true KR20050083098A (en) | 2005-08-25 |
Family
ID=37269388
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020040011695A KR20050083098A (en) | 2004-02-21 | 2004-02-21 | Natural anti-biotics containing the culture broth of leuconostoc kimchii |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR20050083098A (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101253374B1 (en) * | 2006-02-28 | 2013-04-11 | (주)아모레퍼시픽 | Cosmetic composition for controlling anti-acne and anti-comedo |
WO2014058114A1 (en) * | 2012-10-08 | 2014-04-17 | 서울대학교 산학협력단 | Composition, containing cis-cyclo(l-leu-l-pro) or cis-cyclo(l-phe-l-pro), for use as an antimicrobial and antiviral agent, and preparation method therefor |
-
2004
- 2004-02-21 KR KR1020040011695A patent/KR20050083098A/en not_active Application Discontinuation
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101253374B1 (en) * | 2006-02-28 | 2013-04-11 | (주)아모레퍼시픽 | Cosmetic composition for controlling anti-acne and anti-comedo |
WO2014058114A1 (en) * | 2012-10-08 | 2014-04-17 | 서울대학교 산학협력단 | Composition, containing cis-cyclo(l-leu-l-pro) or cis-cyclo(l-phe-l-pro), for use as an antimicrobial and antiviral agent, and preparation method therefor |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR100583836B1 (en) | Natural antibiotic and Composition comprising thereof | |
KR101770902B1 (en) | Method of producing partially purified extracellular metabolite products from bacillus coagulans and biological applications thereof | |
Príncipe et al. | Effectiveness of tailocins produced by Pseudomonas fluorescens SF4c in controlling the bacterial-spot disease in tomatoes caused by Xanthomonas vesicatoria | |
Banerjee et al. | Detection, partial purification and characterization of bacteriocin produced by Lactobacillus brevis FPTLB3 isolated from freshwater fish: Bacteriocin from Lb. brevis FPTLB3 | |
Ahmed et al. | Lactobacillus acidophilus bacteriocin, from production to their application: An overview | |
TW201922224A (en) | Antibacterial cosmetic composition comprising Lactobacillus plantarum culture | |
KR101869221B1 (en) | A novel Weissella cibaria strain and the use thereof | |
KR101495309B1 (en) | New lactic acid bacteria Lactobacillus plantarum DSR KF12 isolated from Gimchi and composition comprising the same | |
Nian et al. | Vishniacozyma victoriae: An endophytic antagonist yeast of kiwifruit with biocontrol effect to Botrytis cinerea | |
Kaur et al. | Membrane-acting bacteriocin purified from a soil isolate Pediococcus pentosaceus LB44 shows broad host-range | |
Budecka et al. | Microbiological contaminants in cosmetics–isolation and characterization | |
KR20160057855A (en) | Lactic acid bacterium separated from kimchii and having antifungal activity, and compositon including it | |
Mandal et al. | Purification and characterization of pediocin produced by Pediococcus acidilactici NCIM 2292 | |
KR102247293B1 (en) | Bacillus subtilis BSC35 strain having antimicrobial activity and uses thereof | |
JP7197204B2 (en) | Novel PEDIOCOCCUS PENTOSACEUS AB160011 Strain and Compositions Containing The Same | |
KR20210154341A (en) | Disinfectant composition comprising Lactobacillus plantarum culture medium | |
KR20050083098A (en) | Natural anti-biotics containing the culture broth of leuconostoc kimchii | |
JP5622110B2 (en) | New lactic acid bacteria | |
Mfon | PRODUCTION OF BACTERIOCIN USING LACTIC ACID BATERIAL ISOLATED FROM FERMENTED FUFU. | |
Babich et al. | Structure and properties of antimicrobial peptides produced by antagonist microorganisms isolated from Siberian natural objects. | |
KR20130039782A (en) | Method of manufacturing mixed micro-organisms | |
KR101766145B1 (en) | Antimicrobial composition comprising citraconic anhydride purified from fermented culture medium of Lactobacillus paraplantarum KNUC25 and isolating method thereof | |
KR20060108964A (en) | Enterococcus faecalis cbt-sl(5), preparation of its culture fluid and composition comprising the same | |
KR100536522B1 (en) | Novel bacteriocin isolated from human skin and the use as therapeutic agent of an acne | |
KR100528641B1 (en) | Leuconostoc citreum gj7 and bacteriocin produced from same |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WITB | Written withdrawal of application |